- Policy
- P-CABs, compete for indication expansion
- by Lee, Tak-Sun Apr 10, 2020 06:29am
- Potassium-Competitive Acid Blocker (P-CAB) drugs, which are called next-generation gastric acid inhibitors, are spurring to expand indications. Currently, the only drug released in Korea is K-Cab by HK inno.N (Tegoprazan). As Vocinti (Vonoprazan by Takeda) is getting permission and is planning to release, Daewoong Pharmaceutical's Fexupra
- Company
- Roche’s ADC Kadcyla retries coverage on early breast cancer
- by Eo, Yun-Ho Apr 10, 2020 06:28am
- Roche is reapplying for Kadcyla’s expanded reimbursement on its early-stage breast cancer indication. According to pharmaceutical industry sources, Roche has recently submitted an application for additional reimbursement on antibody-drug conjugate (ADC) Kadcyla (trastuzumab emtansine). The reimbursement expansion is on the indication a
- Policy
- The first generics for Pristiq ER were approved
- by Lee, Tak-Sun Apr 10, 2020 06:28am
- The generic drugs that avoided the patent of Pristiq ER obtained the item permission. They are expected to be competitive as first generics in the market. The Ministry of Food and Drug Safety approved the approval of four items of Desvenlafaxine, generic for Pristiq ER on the 7th. The generics are Defaxine SR 50·100mg by Whan In, Desve
- Company
- Novartis Korea recorded the largest sales last year
- by An, Kyung-Jin Apr 10, 2020 06:28am
- Novartis Korea recorded the largest sales last year. The first time since the launch of Korea, the sales of representative medicines and new drugs have reached &8361;500 billion. According to Novartis Korea's audit report submitted to the Financial Supervisory Service on the 8th, the company's sales last year were &8361;493.4 billion,
- Company
- Yuhan receives KRW 43 bln for first lazertinib milestone
- by An, Kyung-Jin Apr 10, 2020 06:28am
- On Apr. 8, Yuhan has announced Janssen Biotech would pay out USD 35 million (approximately 43 billion won) to the Korean pharmaceutical company for the licensed out lazertinib’s first milestone. The lazertinib pipeline has reached the first development milestone as clinical study on a combination therapy with Janssen’s anticancer medic
- Policy
- AbbVie does not enforce Kaletra’s patent right
- by Lee, Tak-Sun Apr 9, 2020 09:43pm
- AbbVie’s Kaletra (Lopinavir/Ritonavir), which is used in the clinical field as a treatment for COVID-19, has abandoned patent rights, but there is no news of generic development in Korea This is because the market size of AIDS treatment (HIV-1), which is the main indication of Kaletra, is not large in Korea and is already occupied by othe
- Study: Is convalescent plasma actually effective on COVID-19
- by choi, sun Apr 9, 2020 06:27am
- Following the case reported in China, Korea has published a case study of effective plasma therapy on COVID-19 patients. As the Korean infectious disease control authority has announced its plan to establish a plasma therapy guideline for the COVID-19 patients, the public’s interest on the therapeutic mechanism and effect has heightened. Fo
- Product
- Imported drugs are out of stock due to COVID-19 crisis
- by Kim, Min-Gun Apr 9, 2020 06:27am
- Difficulties in supplying medical products are also continuing in the aftermath of COVID-19, which hit Europe. According to the distribution industry on the 7th, domestic and foreign pharmaceutical companies, such as Kuhnil Pharmaceutical, Daewoong Pharmaceutical, JW Pharmaceutical, and Pfizer Korea, stopped supply due to delays in the pro
- Company
- Social distance postponed tax investigations
- by Nho, Byung Chul Apr 9, 2020 06:26am
- In order to prevent the spread of COVID-19, tax investigations by some pharmaceutical companies in progress are reportedly delayed. According to the industry, Daewoong Bio, Bayer Korea, and Hanmi Pharm are currently under investigation by the National Tax Service. This survey is believed to be a regular tax investigation, not a special tax
- Policy
- Can generic listing negotiation prevent reckless listing?
- by Kim, Jung-Ju Apr 9, 2020 06:26am
- Although some pharmaceutical companies are voicing their concerns over the generic reimbursement negotiation, to be enforced from the second half of the year, some are actually welcoming the new system with an anticipation of positive benefits. Along with the revised drug pricing system coming in effect around the same time, the generic n
